Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics reported 2025 results alongside important clinical updates for its oncology pipeline. In an ongoing registrational-intent Phase 2b trial, ACR-368 showed a confirmed overall response rate of 52% in serous endometrial cancer, a high unmet-need subtype linked to a large share of endometrial cancer deaths. The company is expanding this study by adding Arm 4 to test ACR-368 monotherapy in biomarker-unselected serous patients and has completed exploratory Arm 2 using ultra low-dose gemcitabine sensitization in biomarker-negative subjects.
Early Phase 1 data for ACR-2316 showed favorable tolerability and tumor shrinkage, including in heavily pre-treated lung cancer. For the quarter and year ended December 31, 2025, net loss was $19.0 million and $77.9 million, respectively. Acrivon ended 2025 with $118.6 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the second quarter of 2027.
Acrivon Therapeutics files its annual report describing a clinical-stage oncology business built around its proprietary AP3 phosphoproteomics platform. The company uses AP3 and OncoSignature companion tests to match targeted therapies to patients based on protein signaling rather than genetics alone.
The lead asset, CHK1/2 inhibitor ACR-368, is in a Phase 2b, registrational‑intent program in endometrial cancer, including OncoSignature‑selected and serous “all‑comer” arms, with reported objective responses in heavily pretreated patients. Internally discovered dual WEE1/PKMYT1 inhibitor ACR-2316 is in Phase 1, showing early tumor shrinkage in several solid tumors, while CDK11 inhibitor ACR-6840 is in IND‑enabling studies.
The report highlights continued losses, need for additional funding, dependence on ACR-368 and ACR-2316, complex regulatory and IP requirements, and strong competition in precision oncology. As of June 30, 2025, non‑affiliate equity value was about $20.4 million, and 38,744,446 shares were outstanding as of March 16, 2026.
Acrivon Therapeutics, Inc. reported that its Chief Accounting Officer, Katharine Peterson, received a grant of stock options covering 31,900 shares of common stock. The options were awarded on March 1, 2026 at an exercise price of $0.00 per share as a form of equity compensation.
According to the vesting terms, 25% of the option shares vest on March 1, 2027, with the remaining shares vesting in 36 substantially equal monthly installments after that date. Vesting in all cases requires Ms. Peterson to remain in continuous service through each vesting date.
Acrivon Therapeutics Chief Medical Officer Mirza Mansoor Raza received a grant of stock options covering 174,068 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase. According to the vesting schedule, 25% of the shares vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, subject to his continuous service through each vesting date. Following this award, he holds options on 174,068 shares directly.
Miller Mary reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics reported that Chief Legal Officer Mary Miller received a grant of stock options covering 129,760 shares of common stock on March 1, 2026. According to the vesting terms, 25% of these options vest on March 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, all conditioned on her continued service through each vesting date.
Acrivon Therapeutics, Inc. reported that its Chief Financial Officer, Adam D. Levy, received a grant of stock options. The award covers 132,925 options with an exercise price of $0.00 per share, characterized as a grant or award acquisition rather than an open-market purchase.
According to the vesting terms, 25% of the options vest on March 1, 2027, and the remaining options vest in 36 substantially equal monthly installments after that date. All vesting requires Mr. Levy to remain in continuous service with the company through each vesting date.
Gamelin Erick reported acquisition or exercise transactions in this Form 4 filing.
Acrivon Therapeutics granted Chief Development Officer Erick Gamelin a stock option covering 94,946 shares of common stock. The award is reported as a direct beneficial holding at a stated price of $0.0000 per option unit.
According to the vesting terms, 25% of the shares subject to the option vest on March 1, 2027. The remaining shares vest in 36 substantially equal monthly installments after that date, conditioned on Gamelin’s continuous service through each vesting date.
Acrivon Therapeutics, Inc. reported that Chief Operating Officer Eric Devroe received a grant of stock options covering 186,728 shares of common stock. The Form 4 classifies this as a grant or award acquisition, not an open-market purchase or sale.
According to the vesting terms, 25% of the option vests on March 1, 2027, and the remaining shares vest in 36 substantially equal monthly installments thereafter, provided Devroe remains in continuous service through each vesting date.
Acrivon Therapeutics reported stock option awards to senior executives. The filing shows grants covering 417,210 options and 185,495 options, with exercise rights structured as long-term incentives rather than cash purchases. Twenty-five percent of each grant vests on March 1, 2027, and the remaining options vest in 36 equal monthly installments, conditioned on continued service. Footnotes explain that President and CEO Dr. Peter Blume-Jensen and EVP Dr. Kristina Masson each hold options and disclaim beneficial ownership of their spouse’s securities except for any economic interest.
Acrivon Therapeutics, Inc. is shifting its ACR-368 OncoSignature diagnostic testing fully in-house after completing and certifying an internally owned Clinical Laboratory Improvement Amendment (CLIA) laboratory in Watertown, Massachusetts. This new lab is intended to support development of the company’s current and future targeted therapies.
On February 25, 2026, Acrivon and Akoya Biosciences, a wholly owned subsidiary of Quanterix Corporation, entered into a Termination and Transition Agreement to mutually end their June 17, 2022 OncoSignature Companion Diagnostic Agreement. The termination involves no financial payments between the parties. Quanterix and Acrivon agreed on a transition plan so procedures, materials and know-how from Akoya’s prior ACR-368 OncoSignature work are transferred to Acrivon, while Quanterix continues clinical testing during the changeover to support Acrivon’s registrational-intent Phase 2b study. Effective immediately, Acrivon holds full development and commercialization rights to its proprietary ACR-368 OncoSignature test.